| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 19 |
| 1 | CYCLOPHOSPHAMIDE | 17 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 17 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 17 |
| 4 | GABAPENTIN | 16 |
| 5 | AXICABTAGENE CILOLEUCEL | 14 |
| 6 | CYTARABINE | 14 |
| 7 | ETOPOSIDE | 14 |
| 8 | PANTOPRAZOLE | 14 |
| 9 | ATOVAQUONE | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AVATROMBOPAG MALEATE | 7 | 0.0030 |
| 1 | ATOVAQUONE | 13 | 0.0016 |
| 2 | AXICABTAGENE CILOLEUCEL | 14 | 0.0014 |
| 3 | IDECABTAGENE VICLEUCEL | 1 | 0.0008 |
| 4 | IFOSFAMIDE FOR INJECTION | 13 | 0.0006 |
| 5 | AVELUMAB | 2 | 0.0005 |
| 6 | TAMSULOSIN HYDROCHLORIDE | 10 | 0.0005 |
| 7 | VINCRISTINE SULFATE | 9 | 0.0003 |
| 8 | TRIPTORELIN | 1 | 0.0003 |
| 9 | IRBESARTAN | 13 | 0.0003 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 20 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 20 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 18 |
| 3 | Platinum-based Drug [EPC] | 15 |
| 4 | Angiotensin 2 Receptor Blocker [EPC] | 14 |
| 5 | CD19-directed Chimeric Antigen Receptor [EPC] | 14 |
| 6 | Genetically-modified Autologous T Cells [EPC] | 14 |
| 7 | Topoisomerase Inhibitor [EPC] | 14 |
| 8 | Antimalarial [EPC] | 13 |
| 9 | Antiprotozoal [EPC] | 13 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD19-directed Chimeric Antigen Receptor [EPC] | 14 | 0.0014 |
| 1 | Antimalarial [EPC] | 13 | 0.0012 |
| 2 | Antiprotozoal [EPC] | 13 | 0.0012 |
| 3 | Topoisomerase Inhibitor [EPC] | 14 | 0.0002 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 2 | 0.0001 |
| 5 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 2 | 0.0001 |
| 6 | Alkylating Drug [EPC] | 20 | 0.0001 |
| 7 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 18 | 0.0001 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 20 | 0.0001 |